Literature DB >> 18380601

Treatment of chronic hepatitis B and the implications of viral resistance to therapy.

Stefan Mauss1, Heiner Wedemeyer.   

Abstract

Treatment options for chronic HBV infection have improved considerably in recent years. However, with the increased number of available antiviral drugs, it is also more difficult to select the optimal drug for each individual patient. Antiviral potency, the risk for the development of drug resistance, safety and costs of treatment all need to be considered. In this review, we describe current concepts in the treatment of chronic hepatitis B, with a special focus on the importance of drug resistance and its implications for the long-term management of hepatitis B. Suggestions for avoiding resistance and management of established drug resistance are provided for each individual approved compound.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18380601     DOI: 10.1586/14787210.6.2.191

Source DB:  PubMed          Journal:  Expert Rev Anti Infect Ther        ISSN: 1478-7210            Impact factor:   5.091


  3 in total

1.  Efficient inhibition of hepatitis B virus replication by hepatitis delta virus ribozymes delivered by targeting retrovirus.

Authors:  Chuan-Xi Wang; Yan-Qin Lu; Peng Qi; Long-Hua Chen; Jin-Xiang Han
Journal:  Virol J       Date:  2010-03-17       Impact factor: 4.099

2.  trans-Complementation of HBV rtM204I mutant replication by HBV wild-type polymerase.

Authors:  Richard A Heipertz; Jason L Starkey; Thomas G Miller; Jianming Hu; Harriet C Isom
Journal:  Virology       Date:  2009-04-19       Impact factor: 3.616

3.  HD-03/ES: A Herbal Medicine Inhibits Hepatitis B Surface Antigen Secretion in Transfected Human Hepatocarcinoma PLC/PRF/5 Cells.

Authors:  Sandeep R Varma; R Sundaram; S Gopumadhavan; Satyakumar Vidyashankar; Pralhad S Patki
Journal:  Hepat Res Treat       Date:  2013-04-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.